ToleroMune cat allergy therapy: Phase II started

Circassia began a double-blind, placebo-controlled, Canadian Phase II trial to evaluate multiple doses of 3 nmol of intradermal ToleroMune in 48 patients with confirmed cat allergies and controlled, c...